Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03669042
Other study ID # PHF1801.000-M
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 20, 2018
Est. completion date July 10, 2020

Study information

Verified date July 2020
Source CryoLife, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.


Description:

PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques. The primary endpoint for patients with carotid artery stenosis (CAS) undergoing carotid endarterectomies (CEA) will be rate of ipsilateral central neurologic events; the primary endpoint for all other vascular procedures will be primary patency. The secondary endpoints include all-cause reoperation rate, device-related reoperation rate, explant rate, restenosis rate, secondary patency (hemodialysis access repair (HAR) only) and survival. A goal of 100 patients will be enrolled at approximately 10 sites. The enrollment period will span a minimum of 8 months from Institutional Review Board (IRB) approval and site activation. Candidates for this study are adults who require vascular repair or reconstruction surgery that necessitates the use of a patch. Patients will be consented pre-operatively and enrolled patients will be followed for approximately 6 months after PhotoFix surgery. Data will be collected at 5 time points: baseline (pre-operatively), intra-operatively, 1 month post-operatively, 3 months post-operatively, and 6 months post-operatively.


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date July 10, 2020
Est. primary completion date July 10, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient is undergoing a vascular procedure which falls within the indications for use and requires the use of PhotoFix Decellularized Bovine Pericardium

- Patient's surgery is anticipated to occur within 60 days of consent

- Patient is =18 years old

- Patient is willing and able to comply with the protocol and follow up period

- Patient is willing and able to give written informed consent

Exclusion Criteria:

- Patient's procedure is a revision of a prior arteriotomy or venotomy

- Patient's procedure requires multiple vascular patches in anatomically distinct regions or other prosthetics (e.g. stents)

- Patient has a medical history of abnormal coagulopathy, bleeding, or thromboembolic disease

- Patient has a medical history of severe immunodeficiency disease

- Patient has a medical history of cancer

- Patient has severe visceral disease in heart or active liver disease or icterus

- Patient has a history of cerebrovascular accident (completed stroke) within 3 months of planned surgery

- Patient has a history of atrial fibrillation and requires a patch for carotid endarterectomy repair

- Patient has an active or potential infection at the surgical site

- Patient has used or plans to use immunomodulatory drugs for = 6 months

- Patient has a sensitivity to products of bovine origin

- Patient is currently enrolled in another study

- Patient has a life expectancy of less than 12 months

- Patient is pregnant or breastfeeding or planning on becoming pregnant or unwilling to use medically acceptable methods of birth control

- Patient's procedure is emergent

Study Design


Intervention

Device:
PhotoFix
PhotoFix Patch Implantation

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Brigham and Women's Hospital Boston Massachusetts
United States Iowa Heart Center Des Moines Iowa
United States Columbia University New York New York
United States University of Nebraska Omaha Nebraska
United States University of Utah Salt Lake City Utah
United States Baylor Scott & White Temple Texas
United States Jobst Vascular Institute Toledo Ohio
United States University of Arizona Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
CryoLife, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Central Neurologic Events For cases of carotid endarterectomy (CEA) only: Percent of patients who experienced at least one of the central neurologic events of interest (transient ischemic attack, amaurosis fugax, stroke, carotid occlusion). Up to 6 months, post-op
Primary Primary Patency For all other procedures (non-CEAs): Time from PhotoFix implantation to the time when patency in the vessel is documented as lost. Loss of patency includes loss of previously palpable pulses, presentation of recurrent symptoms, a drop in ABI>0.15 in the case of lower limb artery repair, Doppler ultrasound findings of occlusion, angiography of the affected vessel or a combination of these. Loss of patency will also be considered if an intervention to restore or maintain patency is documented. Up to 6 months, post-op
Secondary Overall Survival Percent of patients surviving Up to 6 months, post-op
Secondary All-Cause Re-operation Rate Percent of patients requiring re-operations Up to 6 months, post-op
Secondary Device-Related Re-operation Rate Percent of patients requiring unplanned re-operations that are documented as possibly, probably or definitely, device-related. Up to 6 months, post-op
Secondary Explant Rate Percent of patients requiring device explants. Explants will include the removal of PhotoFix for any reason after implantation. Up to 6 months, post-op
Secondary Adverse Event Rate Percent of patients who experienced at least one adverse event. Up to 6 months, post-op
Secondary Restenosis Rate Percent of patients who develop stenosis. Stenosis is considered as the recurrence of abnormal narrowing of an artery or vein after corrective surgery. Categorization of stenosis = 50% will occur if data is available. Up to 6 months, post-op
Secondary Secondary Patency For all hemodialysis access repairs only: Time from implantation to the point where the access is abandoned. Up to 6 months, post-op
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1